Drug discovery and development focusing on existing medicines: drug re-profiling strategy
Open Access
- 24 March 2011
- journal article
- Published by Oxford University Press (OUP) in The Journal of Biochemistry
- Vol. 149 (5), 499-505
- https://doi.org/10.1093/jb/mvr032
Abstract
As a new strategy for drug discovery and development, I focus on drug re-profiling as a way to identify new treatments for diseases. In this strategy, the actions of existing medicines, whose safety and pharmacokinetic effects in humans have already been confirmed clinically and approved for use, are examined comprehensively at the molecular level and the results used for the development of new medicines. This strategy is based on the fact that we still do not understand the underlying mechanisms of action of many existing medicines, and as such the cellular responses that give rise to their main effects and side effects are yet to be elucidated. To this extent, identification of the mechanisms underlying the side effects of medicines offers a means for us to develop safer drugs. The results can also be used for developing existing drugs for use as medicines for the treatment of other diseases. Promoting this research strategy could provide breakthroughs in drug discovery and development.Keywords
This publication has 42 references indexed in Scilit:
- Prostaglandin E2 Stimulates the Production of Amyloid-β Peptides through Internalization of the EP4 ReceptorPublished by Elsevier BV ,2009
- NSAIDs suppress the expression of claudin-2 to promote invasion activity of cancer cellsCarcinogenesis: Integrative Cancer Research, 2008
- Cyclooxygenase-2 inhibition improves amyloid-β-mediated suppression of memory and synaptic plasticityBrain, 2008
- A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndromeScandinavian Journal of Gastroenterology, 2008
- Endoplasmic reticulum chaperones inhibit the production of amyloid-β peptidesBiochemical Journal, 2007
- Hsp70 inhibits lipopolysaccharide‐induced NF‐κB activation by interacting with TRAF6 and inhibiting its ubiquitinationFEBS Letters, 2006
- Involvement of Intracellular Ca2+ Levels in Nonsteroidal Anti-inflammatory Drug-induced ApoptosisPublished by Elsevier BV ,2005
- Modulation of neurodegeneration by molecular chaperonesNature Reviews Neuroscience, 2005
- Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosisCell Death & Differentiation, 2004
- Topical minoxidil solution (1% and 5%) in the treatment of alopecia areataJournal of the American Academy of Dermatology, 1987